Positive effect of erythromycin on ineffective oesophageal motility in laryngopharyngeal reflux patients: Room for a novel treatment?

INTRODUCTION

Laryngopharyngeal reflux (LPR) management guidelines are currently derived from the management of gastroesophageal reflux disease (GORD) which has been shown to be poorly effective in controlling symptoms for these patients. Erythromycin is a macrolide antibiotic that has been used extensively as a prokinetic agent for the gastrointestinal tract. The management of LPR with prokinetics is a novel therapy being investigated with regard to its effectiveness. The purpose of this pilot study was to observe the effect of erythromycin on oesophageal motility with high resolution manometry (HRM) to establish if further study is warranted regarding its utility in management.

METHODS

Consecutive patients were retrospectively identified from a prospectively maintained database at a single centre of patients with findings suggestive of LPR who had also undergone HRM. These patients all received lifestyle modification and erythromycin 250 mg BD with repeat HRM after 6 weeks of therapy.

RESULTS

16 patients met inclusion criteria. Mean age was 56.2 ± 14.9. Mean ineffective swallows were 54.38% ± 41.3% compared with 34.4% ± 35.2% pre and post-erythromycin therapy (p = 0.018). Mean distal contractile integral at baseline was 793.61 ± 854.96 mmHg at baseline increasing to 1347 ± 1094.73 mmHg after erythromycin therapy (p = 0.013). IRP also showed improvement from 8.99 ± 7.58 increasing to 10.93 ± 7.9 mmHg (p = 0.045). Subgroup analysis of patients with ineffective oesophageal motility reinforced above findings as well as increase in the amount of 'normal' peristalsis.

CONCLUSION

This pilot study shows early evidence that erythromycin improves oesophageal motility. Further study is warranted to explore these findings in more detail.